NEW YORK—November 21, 2008
Neither is true.
It is important to note that the study reported in these news stories was a proof-of-concept study in mice, not a clinical trial involving human subjects. While the mouse study does point to a new way of thinking about how pregnancies are lost, and may in the future point to a new type of treatment for APS-induced pregnancy loss, clinical studies are necessary before the use of statins during human pregnancy can be deemed safe.
Hospital for Special Surgery
Stephen A. Paget, M.D., FACP, FACR
Physician-in-Chief and Chairman of the Division of Rheumatology
Michael D. Lockshin, MD, MACR
Director, Barbara Volcker Center for Women and Rheumatic Disease
Co-Director, Mary Kirkland Center for Lupus Research
 Redecha P, et al: Neutrophil activation by the tissue factor/Factor VIIa/PAR2 axis mediates fetal death in a mouse model of antiphospholipid syndrome. J Clin Invest 2008 October 1; 118(10): 3453–3461.
About Hospital for Special Surgery
Founded in 1863, Hospital for Special Surgery (HSS) is a world leader in orthopedics, rheumatology and rehabilitation. HSS is nationally ranked No. 1 in orthopedics, No. 3 in rheumatology and No. 7 in geriatrics by U.S. News & World Report (2015-2016), and is the first hospital in New York State to receive Magnet Recognition for Excellence in Nursing Service from the American Nurses Credentialing Center four consecutive times. HSS has one of the lowest infection rates in the country. HSS is an affiliate of Weill Cornell Medical College and as such all Hospital for Special Surgery medical staff are faculty of Weill Cornell. The hospital's research division is internationally recognized as a leader in the investigation of musculoskeletal and autoimmune diseases. Hospital for Special Surgery is located in New York City and online at www.hss.edu.